Blog

FDA and WHOSTP discuss increasing clinical trials access and lowering barriers to participation

Photo taken from FDA Oncology/X

Jul 3, 2024, 04:18

FDA and WHOSTP discuss increasing clinical trials access and lowering barriers to participation

FDA Oncology shared on X:

“FDA Oncology Center’s Paul Kluetz, Rick Pazdur, Donna Rivera attended the White House Office of Science & Technology Policy Clinical Trials Forum yesterday to meet with stakeholders to discuss increasing clinical trials access and lowering barriers to participation to improve health outcomes.”

Source: FDA Oncology/X
.

cancer clinical trials access Clinical Trials Forum Donna Rivera FDA FDA Oncology health outcomes Office of Science & Technology Policy OncoDaily Oncology Paul Kluetz Rick Pazdur White House

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage